Dublin, Ireland – 19 March 2021: Cosmo Pharmaceuticals NV (SIX: COPN) invites investors, financial analysts and business/lifescience journalists for a telephone conference on 26 March 2021 with CEO Alessandro Della Chà and CFO Niall Donnelly to discuss the 2020 results and 2021 outlook of the company.
Date: Friday, 26 March 2021
Time: 02:00 pm CET
Dial-in numbers:
Switzerland / Europe +41 (0) 58 310 50 00
United Kingdom +44 (0) 207 107 06 13
United States +1 (1) 631 570 56 13
The presentation and press release as well as the Annual Report 2020 will be available for download as of 07:00 am CET on 26 March 2021 on www.cosmopharma.com
About Cosmo Pharmaceuticals
Cosmo is a specialty pharmaceutical company focused on developing and commercialising products to treat selected gastrointestinal disorders and improve endoscopy quality measures through aiding the detection of colonic lesions. Cosmo has also developed medical devices for endoscopy and has recently entered into a partnership with Medtronic for the global distribution of GI Genius™ its artificial intelligence device for use in coloscopies and GI procedures. Cosmo has licensed Aemcolo® to Red Hill Biopharma Ltd. for the US and has licensed Relafalk® to Dr. Falk Gmbh for the EU and other countries. For additional information on Cosmo and its products please visit the Company’s website: www.cosmopharma.com
Calendar
2020 Full Year Results and 2021 Outlook March 26, 2021
Annual General Meeting, Amsterdam May 28, 2021
Contact
Niall Donnelly, CFO & Head of Investor Relations
Cosmo Pharmaceuticals N.V.
Tel: +353 1 817 03 70
ndonnelly@cosmopharma.com